Retatrutide and tirzepatide come from the same broad family of incretin peptides, but they differ in how many receptors they target and, crucially, in how far along they are. Tirzepatide is FDA-approved and widely used, while retatrutide remains investigational, so the evidence behind each is not on equal footing.
Reviewed for accuracy · Last reviewed July 7, 2026The clearest practical difference is regulatory. Tirzepatide has an approved label, a defined titration, and Phase 3 evidence, whereas retatrutide is still investigational with no approved dose or long-term human safety record.
Mechanistically, retatrutide adds a third receptor target (glucagon) on top of the GLP-1/GIP combination tirzepatide uses. Whether that translates into a meaningful real-world difference is not something the current evidence lets anyone state as fact.
Both were studied as once-weekly subcutaneous injections with gradual dose escalation, and both reported predominantly gastrointestinal side effects that were dose-related. Neither of these is a substitute for medical advice about which, if either, is appropriate.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.